Evidence map›Paper›PMID 32146785›Full record

ArticleAnnals of coloproctology2020

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Mitomycin C Used for Colorectal Peritoneal Carcinomatosis.

Seung Jae Roh, Sung Chan Park, Jaehee Choi, Joon Sang Lee, Dong Woon Lee, Chang Won Hong, Kyung Su Han, Hyoung Chul Park, Dae Kyung Sohn, Jae Hwan Oh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of coloproctology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. What is the ideal management of Krukenberg syndrome?Journal of surgical case reports · 2022
    Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Seung Jae RohCenter for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Sung Chan ParkCenter for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Jaehee ChoiCenter for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Joon Sang LeeCenter for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Dong Woon LeeCenter for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Chang Won HongCenter for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Kyung Su HanCenter for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Hyoung Chul ParkCenter for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Dae Kyung SohnCenter for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Jae Hwan OhCenter for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
National Cancer Center · KR

Funding

National Cancer Center 1810191
6 · The paper itself

Abstract

purposeThis study aimed to assess the evaluation of clinical outcomes and consequences of complications after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for the peritoneal carcinomatosis (PC) from colorectal cancer.

methodsA total 26 patients underwent CRS and HIPEC for PC from colorectal cancer between March 2009 and April 2018. All the patients underwent CRS with the purpose of complete or near-complete cytoreduction. Intraoperative HIPEC was performed simultaneously after the CRS. Mitomycin C was used as chemotherapeutic agent for HIPEC.

resultsMedian disease-free survival was 27.8 months (range, 13.4-42.2 months). Median overall survival was 56.0 months (range, 28.6-83.5 months). The mean peritoneal cancer index (PCI) was 8.73 ± 5.54. The distributions thereof were as follows: PCI <10, 69.23%; PCI 10-19, 23.08%; and PCI ≥20, 7.69%. The completeness of cytoreduction was 96.2% of patients showed CC-0, with 3.8% achieved CC-1. The mean operation time was 8.5 hours, and the mean postoperative hospital stay was 21.6 days. The overall rate of early postoperative complications was 88.5%; the rate of late complications was 34.6%. In the early period, most complications were grades I-II complications (65.4%), compared to grades III-V (23.1%). All late complications, occurring in 7.7% of patients, were grades III-V. There was no treatment-related mortality.

conclusionAlthough the complication rate was approximately 88%, but the rate of severe complication rate was low. In selective patients with peritoneal recurrence, more aggressive strategies for management, such as CRS with HIPEC, were able to be considered under the acceptable general condition and life-expectancy.

Indexed as

Colorectal neoplasmsCytoreductive surgeryHyperthermic intraperitoneal chemotherapyPeritoneal carcinomatosis

Identifiers

PMID32146785
PMCPMC7069674
OpenAlexW3009953065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.